

# Enrique M Ocio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5155219/publications.pdf>

Version: 2024-02-01

131  
papers

8,379  
citations

44069

48  
h-index

48315

88  
g-index

134  
all docs

134  
docs citations

134  
times ranked

9039  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their Influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e241-e249.	0.4	2
2	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.4	11
3	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	7.2	81
4	Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem cell transplantation is a prognostic marker of longer progression-free survival and overall survival. <i>British Journal of Haematology</i> , 2022, 198, 278-287.	2.5	6
5	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 68.	6.2	8
6	Melflufen for the treatment of multiple myeloma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 371-382.	3.1	3
7	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. <i>Leukemia</i> , 2021, 35, 245-249.	7.2	10
8	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1 acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. <i>British Journal of Haematology</i> , 2021, 192, 522-530.	2.5	8
9	6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. <i>British Journal of Haematology</i> , 2021, 192, 843-852.	2.5	28
10	Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. <i>Cells</i> , 2021, 10, 559.	4.1	2
11	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
12	LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8051-TPS8051.	1.6	2
13	ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM) – Optimal dose, updated efficacy and safety results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8037-8037.	1.6	4
14	Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression. <i>Cancers</i> , 2021, 13, 2542.	3.7	15
15	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	6.2	14
16	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. <i>Blood</i> , 2021, 138, 1583-1589.	1.4	11
17	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	7.2	43
18	Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. <i>Haematologica</i> , 2020, 105, e116-e120.	3.5	38

#	ARTICLE	IF	CITATIONS
19	Filanesib for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs, 2020, 29, 5-14.	4.1	18
20	Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma. Cancers, 2020, 12, 2743.	3.7	9
21	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. Cancers, 2020, 12, 3615.	3.7	7
22	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia, 2020, 34, 3298-3309.	7.2	37
23	ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety. Blood, 2020, 136, 9-10.	1.4	15
24	Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology, 2020, 38, 8529-8529.	1.6	5
25	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. Journal of Clinical Medicine, 2020, 9, 3120.	2.4	35
26	Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. Leukemia and Lymphoma, 2019, 60, 462-470.	1.3	11
27	Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematology, 2019, 6, e459-e469.	4.6	174
28	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research, 2019, 85, 106197.	0.8	16
29	Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. Cells, 2019, 8, 1432.	4.1	24
30	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet, The, 2019, 394, 2096-2107.	13.7	435
31	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. Annals of Hematology, 2019, 98, 2139-2150.	1.8	39
32	The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. Leukemia, 2019, 33, 2924-2933.	7.2	49
33	Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study. British Journal of Haematology, 2019, 186, e117-e121.	2.5	58
34	Induction Therapy for Newly Diagnosed Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e176-e186.	3.8	28
35	Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature. Blood Cancer Journal, 2019, 9, 36.	6.2	11
36	Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma. HemaSphere, 2019, 3, e192.	2.7	6

#	ARTICLE	IF	CITATIONS
37	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.	7.2	20
38	ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). <i>Blood</i> , 2019, 134, 3124-3124.	1.4	12
39	Risk Adapted Antifungal Strategy in Allogeneic Stem Cell Transplantation. Should We Change the Current Guidelines?. <i>Blood</i> , 2019, 134, 5655-5655.	1.4	0
40	Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role. <i>Leukemia</i> , 2018, 32, 2427-2434.	7.2	8
41	Aggressive primary cutaneous <sc>CD</sc>30+ lymphoproliferative disorder in an organ transplant recipient in sustained complete remission with brentuximab vedotin. <i>International Journal of Dermatology</i> , 2018, 57, e153-e155.	1.0	2
42	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. <i>Haematologica</i> , 2018, 103, e544-e548.	3.5	13
43	Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant. <i>Blood</i> , 2018, 132, 595-595.	1.4	22
44	Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. <i>Haematologica</i> , 2017, 102, 168-175.	3.5	9
45	Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. <i>Haematologica</i> , 2017, 102, 922-931.	3.5	34
46	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017, 31, 2443-2448.	7.2	259
47	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. <i>Haematologica</i> , 2017, 102, 2113-2124.	3.5	19
48	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 6602-6615.	7.0	25
49	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. <i>Journal of Hematology and Oncology</i> , 2017, 10, 127.	17.0	25
50	Waldenström's Macroglobulinemia Immunophenotype. , 2017, , 21-34.		3
51	The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care. <i>Clinical Cancer Research</i> , 2017, 23, 225-238.	7.0	42
52	Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 567-569.	2.4	5
53	Lenalidomide in combination with Râ€<sc>ESHAP</sc> in patients with relapsed or refractory diffuse large Bâ€cell lymphoma: a phase 1b study from <sc>GELTAMO</sc> group. <i>British Journal of Haematology</i> , 2016, 173, 245-252.	2.5	24
54	Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 1096-1100.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. <i>Leukemia</i> , 2016, 30, 2026-2031.	7.2	19
56	Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. <i>Blood</i> , 2016, 127, 1896-1906.	1.4	81
57	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	1.4	144
58	Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. <i>Blood</i> , 2016, 127, 3165-3174.	1.4	129
59	Phase I/II study of weekly PM00104 (Zalypsis <sup>®</sup> ) in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016, 172, 625-628.	2.5	8
60	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. <i>Haematologica</i> , 2015, 100, 1294-1300.	3.5	27
61	The cellular origin and malignant transformation of Waldenström macroglobulinemia. <i>Blood</i> , 2015, 125, 2370-2380.	1.4	80
62	The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, e53-e55.	3.5	41
63	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. <i>Leukemia</i> , 2015, 29, 705-714.	7.2	72
64	Treatment for patients with newly diagnosed multiple myeloma in 2015. <i>Blood Reviews</i> , 2015, 29, 387-403.	5.7	48
65	PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. <i>Leukemia</i> , 2015, 29, 2110-2113.	7.2	170
66	Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. <i>Haematologica</i> , 2015, 100, 1207-1213.	3.5	20
67	Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, e289-e291.	3.5	10
68	Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. <i>Leukemia</i> , 2015, 29, 1186-1194.	7.2	71
69	Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines. <i>PLoS ONE</i> , 2014, 9, e92378.	2.5	23
70	Multiparameter flow cytometry for the identification of the Waldenström <sup>™</sup> clone in IgM-MGUS and Waldenström <sup>™</sup> Macroglobulinemia: new criteria for differential diagnosis and risk stratification. <i>Leukemia</i> , 2014, 28, 166-173.	7.2	76
71	Future agents and treatment directions in multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 127-141.	2.2	30
72	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 504-516.	4.1	7

#	ARTICLE	IF	CITATIONS
73	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). <i>Leukemia</i> , 2014, 28, 525-542.	7.2	214
74	Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. <i>Blood</i> , 2014, 124, 1300-1303.	1.4	67
75	Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease. <i>Clinical Cancer Research</i> , 2014, 20, 1542-1554.	7.0	75
76	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
77	Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. <i>Blood</i> , 2014, 124, 3029-3031.	1.4	40
78	Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial. <i>Blood</i> , 2014, 124, 178-178.	1.4	6
79	Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. <i>Oncotarget</i> , 2014, 5, 8284-8305.	1.8	43
80	A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. <i>Leukemia</i> , 2013, 27, 2056-2061.	7.2	78
81	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. <i>Leukemia</i> , 2013, 27, 430-440.	7.2	112
82	Response assessment in Waldenström macroglobulinaemia: update from the 11th International Workshop. <i>British Journal of Haematology</i> , 2013, 160, 171-176.	2.5	226
83	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. <i>Investigational New Drugs</i> , 2013, 31, 200-205.	2.6	11
84	Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma. <i>Seminars in Oncology</i> , 2013, 40, 618-633.	2.2	24
85	MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. <i>Leukemia</i> , 2013, 27, 1722-1728.	7.2	238
86	Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. <i>Haematologica</i> , 2013, 98, 640-648.	3.5	75
87	Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. <i>Clinical Cancer Research</i> , 2013, 19, 2677-2687.	7.0	45
88	Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. <i>Blood</i> , 2013, 122, 3591-3598.	1.4	131
89	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. <i>Haematologica</i> , 2013, 98, 79-86.	3.5	132
90	Multiple myeloma: treatment evolution. <i>Hematology</i> , 2012, 17, s3-s6.	1.5	13

#	ARTICLE	IF	CITATIONS
91	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. <i>Haematologica</i> , 2012, 97, 1110-1114.	3.5	34
92	Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMiDs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1075-1087.	4.1	19
93	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. <i>PLoS ONE</i> , 2012, 7, e34914.	2.5	61
94	Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 257-269.	1.8	7
95	BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. <i>Blood</i> , 2011, 118, 3419-3425.	1.4	123
96	Differential Diagnosis of IgM MGUS and WM According to B-Lymphoid Infiltration by Morphology and Flow Cytometry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 93-95.	0.4	16
97	The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. <i>Blood</i> , 2011, 117, 3613-3616.	1.4	59
98	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. <i>Haematologica</i> , 2011, 96, 687-695.	3.5	13
99	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. <i>Haematologica</i> , 2010, 95, 794-803.	3.5	144
100	The DAC system and associations with multiple myeloma. <i>Investigational New Drugs</i> , 2010, 28, 28-35.	2.6	15
101	Novel treatment regimens for Waldenström's macroglobulinemia. <i>Expert Review of Hematology</i> , 2010, 3, 339-350.	2.2	14
102	Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 120-126.	1.6	207
103	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. <i>Leukemia</i> , 2009, 23, 2265-2274.	7.2	58
104	International prognostic scoring system for Waldenström macroglobulinemia. <i>Blood</i> , 2009, 113, 4163-4170.	1.4	366
105	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. <i>Blood</i> , 2009, 113, 3781-3791.	1.4	78
106	p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. <i>British Journal of Haematology</i> , 2008, 141, 598-606.	2.5	53
107	The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. <i>British Journal of Haematology</i> , 2008, 141, 470-482.	2.5	35
108	New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. <i>Lancet Oncology</i> , 2008, 9, 1157-1165.	10.7	116



#	ARTICLE	IF	CITATIONS
109	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. <i>Haematologica</i> , 2008, 93, 57-66.	3.5	56
110	Aplidin, a Marine Organismâ€‘Derived Compound with Potent Antimyeloma Activity <i>In vitro</i> and <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 5216-5225.	0.9	98
111	5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1718-1727.	4.1	154
112	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. <i>Blood</i> , 2007, 110, 3744-3752.	1.4	144
113	JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis <i>in vitro</i> and <i>in vivo</i> in human multiple myeloma cells. <i>Blood</i> , 2007, 110, 709-718.	1.4	139
114	Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. <i>Leukemia</i> , 2007, 21, 541-549.	7.2	187
115	Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of $\beta$ -catenin/TCF pathway. <i>Leukemia</i> , 2007, 21, 535-540.	7.2	28
116	Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. <i>Leukemia</i> , 2007, 21, 797-804.	7.2	26
117	6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. <i>British Journal of Haematology</i> , 2007, 136, 80-86.	2.5	109
118	BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. <i>British Journal of Haematology</i> , 2007, 136, 414-423.	2.5	49
119	Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.. <i>Blood</i> , 2007, 110, 1178-1178.	1.4	14
120	The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces <i>In Vitro</i> and <i>In Vivo</i> Antimyeloma Activity.. <i>Blood</i> , 2007, 110, 1515-1515.	1.4	2
121	Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 380-383.	1.4	107
122	<i>In vivo</i> and <i>in vitro</i> cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. <i>British Journal of Haematology</i> , 2006, 134, 37-44.	2.5	18
123	Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 821-822.	2.4	15
124	The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance. <i>Cancer Research</i> , 2006, 66, 5781-5789.	0.9	233
125	Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. <i>Leukemia</i> , 2005, 19, 1088-1091.	7.2	43
126	Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. <i>American Journal of Hematology</i> , 2005, 78, 302-305.	4.1	66



#	ARTICLE	IF	CITATIONS
127	CD34 <sup>+</sup> cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2005, 46, 177-183.	1.3	24
128	Immunophenotypic and Cytogenetic Comparison of Waldenström's Macroglobulinemia with Splenic Marginal Zone Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 241-245.	2.1	47
129	Cell Cycle Analysis of Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 250-252.	2.1	5
130	Gene Expression Profiling of B-Lymphocyte and Plasma Cell Populations from Waldenström's Macroglobulinemia. Comparison with Expression Patterns of the Same Cell-Counterparts from Other B-Cell Neoplasms. <i>Blood</i> , 2005, 106, 503-503.	1.4	2
131	Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study. <i>Bone Marrow Transplantation</i> , 2004, 34, 729-738.	2.4	40